Clinical Trial Update: Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Update on a Phase 2 clinical trial evaluating neoadjuvant SBRT combined with lenvatinib and pucotenlimab for resectable hepatocellular carcinoma, including pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pucotenlimab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Resectable Hepatocellular Carcinoma, Macrovascular Invasion | Phase 2 | Status: ACTIVE_NOT_RECRUITING